Cell therapy: Showing cells the way home
Name
Heinelt-2015-Cell therapy.pdf
Size
511.01 KB
Format
Adobe PDF
Checksum (MD5)
f8af0696778f30ffaec751f70326576c
Author(s)
Heinelt, Martina
Karp, Jeffrey Michael
Levy, Oren
Date Issued
July 2015
Journal
Oncotarget
Publisher
Impact Journals/National Center for Biotechnology Information (U.S.)
Citation
Heinelt, Martina, Jeffrey M. Karp, and Oren Levy. "Cell therapy: Showing cells the way home." Oncotarget 6(20) (2015). © 2015 Impact Journals, LLC.
Version
Final published version
Abstract
The clinical potential of cell-based therapies is limited by poor targeting of systemically infused cells to diseased tissues. In our recent study, we have
developed a multi-step screening platform to identify small molecules that boost the homing properties of mesenchymal stem cells (MSCs) to sites of inflammation. First, a medium-throughput screen was designed to identify small molecules that upregulate surface expression of the homing integrin, cd11a (integrin αL). Ro-31-8425, a kinase inhibitor, was identified as the most potent inducer of cd11a surface expression, and was also shown to significantly increase MSC firm adhesion to the endothelial ligand of cd11a, ICAM-1, using a microfluidics-based firm adhesion assay. Finally, systemically infused Ro-31-8425-pretreated MSCs displayed improved homing to sites of inflammation and a superior anti-inflammatory impact in a murine ear inflammation model.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=4883
